Terazosin Repurposing Study in ALS (TRUST)
Terazosin RepUrposing STudy in ALS (TRUST) is a single-centre, interventional, open-label, non-randomised, non-controlled proof of concept study, funded by the My Name’5 Doddie Foundation, to assess the neuroprotective effects of terazosin in patients with ALS.
TRUST is managed by Dr Elizabeth Gray (email@example.com) in collaboration with the Oxford Clinical Trials Research Unit (OCTRU).
Our collaborator Professor Tom Gillingwater (University of Edinburgh) and his team attend our TRUST trial management group meetings on a monthly basis to discuss trial progress.
Recruitment is well advanced and we will continue until we reach our target which is currently scheduled to be in March 2024. Results will be available later in the year.